C-peptide replacement improves weight gain and renal function in diabetic rats
Recent experimental and clinical data suggest that C-peptide replacement during type 1 diabetes exerts beneficial effects on diabetic nephropathy. The aim of this study was to determine if physiological C-peptide administration in replacement dose during 28 days had beneficial effects on metabolic s...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolism 2006-06, Vol.32 (3), p.223-228 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 3 |
| container_start_page | 223 |
| container_title | Diabetes & metabolism |
| container_volume | 32 |
| creator | Rebsomen, L Pitel, S Boubred, F Buffat, C Feuerstein, JM Raccah, D Vague, P Tsimaratos, M |
| description | Recent experimental and clinical data suggest that C-peptide replacement during type 1 diabetes exerts beneficial effects on diabetic nephropathy. The aim of this study was to determine if physiological C-peptide administration in replacement dose during 28 days had beneficial effects on metabolic status and renal functions in type-1 diabetic rats.
Four groups of rats were investigated: a non diabetic group treated with buffer (C group, n=6), three streptozotocin diabetic-induced groups treated with either buffer (D group, n=6), insulin (D-I group, n=6) or rat homologous C-peptide (D-C group, n=6). Weight gain was measured every week. All animals were housed in metabolic cages on day 28 for assessment of metabolic data. Blood and urine samples were collected to allow measurement of plasmatic osmolality, C-peptide concentration, sodium, and glucose losses and proteinuria. Glomerular filtration rate (GFR) was determined by crea-tinine clearance.
All streptozotocin-treated animals were diabetic. Glycaemic control (mg/dl), was markedly improved in D-I (133±65) when compared with either D (547±49, P |
| doi_str_mv | 10.1016/S1262-3636(07)70272-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68576878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1262363607702720</els_id><sourcerecordid>68576878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-87e2765f1f9c1a3799d0856340dc7a367656315a93abb1a1e9f0c6f8555610633</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEYjD4CaBeQHAoJM2apCeEJr4kBAfgHHmpC0FtWpJsiH9PYEM7cooVP7ZfPYQcMHrGKBPnT6wQRc4FFydUnkpayCKnG2SHKalyJhXdTPUfMiK7IbxTyoqKq20yYkJWFa_UDnmY5gMO0daYeRxaMNihi5ntBt8vMGSfaF_fYvYK1mXg6gQ5aLNm7ky0vcvSb21hhtGazEMMe2SrgTbg_uodk5frq-fpbX7_eHM3vbzPDa94zJXEQoqyYU1lGPAUpqaqFHxCayOBi9QTnJVQcZjNGDCsGmpEo8qyFIwKzsfkeLk3xfyYY4i6s8Fg24LDfh60UKUUyUQCyyVofB-Cx0YP3nbgvzSj-kek_hWpfyxpKvWvSE3T3OHqwHzWYb2eWplLwNEKgGCgbTw4Y8OaS7fVZCITd7HkMOlYWPQ6GIvOYG09mqjr3v4T5RsOmI6G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68576878</pqid></control><display><type>article</type><title>C-peptide replacement improves weight gain and renal function in diabetic rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rebsomen, L ; Pitel, S ; Boubred, F ; Buffat, C ; Feuerstein, JM ; Raccah, D ; Vague, P ; Tsimaratos, M</creator><creatorcontrib>Rebsomen, L ; Pitel, S ; Boubred, F ; Buffat, C ; Feuerstein, JM ; Raccah, D ; Vague, P ; Tsimaratos, M</creatorcontrib><description><![CDATA[Recent experimental and clinical data suggest that C-peptide replacement during type 1 diabetes exerts beneficial effects on diabetic nephropathy. The aim of this study was to determine if physiological C-peptide administration in replacement dose during 28 days had beneficial effects on metabolic status and renal functions in type-1 diabetic rats.
Four groups of rats were investigated: a non diabetic group treated with buffer (C group, n=6), three streptozotocin diabetic-induced groups treated with either buffer (D group, n=6), insulin (D-I group, n=6) or rat homologous C-peptide (D-C group, n=6). Weight gain was measured every week. All animals were housed in metabolic cages on day 28 for assessment of metabolic data. Blood and urine samples were collected to allow measurement of plasmatic osmolality, C-peptide concentration, sodium, and glucose losses and proteinuria. Glomerular filtration rate (GFR) was determined by crea-tinine clearance.
All streptozotocin-treated animals were diabetic. Glycaemic control (mg/dl), was markedly improved in D-I (133±65) when compared with either D (547±49, P<0.05) or D-C (520±48, P<0.05) groups. Conversely, weight gain during the study, was improved in D-I and D-C as compared with D animals (135±13 and 41±18 vs 18±21 respectively), despite different glycaemic control. Diabetes-induced glomerular hyperfiltration (ml/min/kg), urinary protein leakage (g/kg/day), and Na urinary losses (mmol/100 g/day) respectively, were significantly (P<0.05) reduced in D-C (3.95±0.6; 0.08±0.06; 1.5±0.9) in comparison with D (4.95±0.8; 0.18±0.16; 3.7±2.1) and D-I (5±0.9; 0.19±0.11; 2.7±0.8) animals. Plasmatic osmolality was significantly increased in D group whereas there were no differences between C group and D-C group. Food and water intakes, urinary volume as well as urinary glucose losses were not significantly different between D-C and D groups.
C-peptide administration in replacement dose to strep-tozotocin diabetic rats induces weight gain regardless hyperglycaemia or glycosuria. Diabetic animals supplemented with C-peptide exhibit better renal function resulting in reduced urinary sodium waste and protein excretion together with reduction of the diabetes-induced glomerular hyperfiltration.
La supplémentation en peptide-C améliore la prise de poids et les fonctions rénales du rat diabétique
Des données expérimentales et cliniques récentes ont montré que la supplémentation en peptide-C avait des effets bénéfiques sur l'atteinte rénale du diabète de type 1. L'objectif de ce travail était de déterminer les effets d'une supplémentation en peptide-C à des doses physiologiques, pendant 28 jours, sur le statut métabolique et les fonctions rénales du rat diabétique.
Quatre groupes de rats ont été étudiés : un groupe de rats non diabétiques supplémentés avec une solution saline (groupe C, n = 6) et trois groupes de rats diabétiques (streptozotocine, IV), sup-plémentés respectivement avec une solution saline (groupe D, n = 6), de l'insuline (groupe D-I, n = 6) et du peptide-C (groupe D-C, n = 6). Les rats ont été pesés chaque semaine. À la fin de la période d'étude, les animaux ont été placés dans des cages métaboliques. Différents paramètres biologiques ont été mesurés : l'osmolalité plasmatique, les concentrations plasmatiques en peptide-C, sodium et glucose, la glycosurie, la natriurèse et la protéinurie. Le débit de filtration glomérulaire (GFR) a été déterminé par la clairance de la créatinine.
Tous les rats traités avec la streptozotocine étaient diabétiques. La glycémie (mg/ml) a été rétablie dans le groupe D-I (133 ± 65) comparé au groupe D (547 ± 49, P < 0,05) ou D-C (520 ± 48, P < 0,05). La prise de poids a été améliorée dans les groupes D-I et D-C comparés au groupe D (135 ± 13 et 41 ± 18 vs 18 ± 21 respectivement), indifféremment de la glycémie. L'hyperfiltration glomérulaire (ml/min/kg) induite par le diabète ainsi que la protéinurie (g/kg/jour) et la perte de sodium (mmol/100 g/day) ont été significativement réduites (P < 0,05) dans le groupe D-C (3,95 ± 0,6; 0,08 ± 0,06; 1,5 ± 0,9) comparé aux groupes D (4,95 ± 0,8; 0,18 ± 0,16; 3,7 ± 2,1) et D-I (5 ± 0,9; 0,19 ± 0,11; 2,7 ± 0,8). Les quantités de nourriture et d'eau, le volume urinaire, ainsi que la glycosurie n'étaient pas significative-ment différents entre les groupes D-C et D.
La supplémentation en peptide-C pendant un mois de rats diabétiques améliore la prise de poids indépendamment de l'hyperglycémie ou de la glycosurie. Elle entraîne également une amélioration de la fonction rénale, par comparaison aux rats diabétiques non supplémentés, en réduisant la perte de sodium urinaire, la protéinurie et l'hyperfiltration glomérulaire.]]></description><identifier>ISSN: 1262-3636</identifier><identifier>EISSN: 1878-1780</identifier><identifier>DOI: 10.1016/S1262-3636(07)70272-0</identifier><identifier>PMID: 16799398</identifier><language>eng</language><publisher>Paris: Elsevier Masson SAS</publisher><subject>Animals ; Biological and medical sciences ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; C-peptide ; C-Peptide - blood ; C-Peptide - therapeutic use ; Diabetes Mellitus, Experimental - blood ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - physiopathology ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - prevention & control ; Diabetic nephropathy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Glomerular hyperfiltration ; Hyperfiltration glomérulaire ; Insulin - blood ; Kidney - drug effects ; Kidney - physiopathology ; Kidneys ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; Néphropathie diabétique ; Peptide-C ; Perte de sodium ; Prise de poids ; Proteinuria ; Protéinurie ; Rats ; Rats, Sprague-Dawley ; Sodium - urine ; Sodium losses ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland ; Weight gain ; Weight Gain - drug effects</subject><ispartof>Diabetes & metabolism, 2006-06, Vol.32 (3), p.223-228</ispartof><rights>2006 Elsevier Masson SAS</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-87e2765f1f9c1a3799d0856340dc7a367656315a93abb1a1e9f0c6f8555610633</citedby><cites>FETCH-LOGICAL-c393t-87e2765f1f9c1a3799d0856340dc7a367656315a93abb1a1e9f0c6f8555610633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1262363607702720$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17838447$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16799398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rebsomen, L</creatorcontrib><creatorcontrib>Pitel, S</creatorcontrib><creatorcontrib>Boubred, F</creatorcontrib><creatorcontrib>Buffat, C</creatorcontrib><creatorcontrib>Feuerstein, JM</creatorcontrib><creatorcontrib>Raccah, D</creatorcontrib><creatorcontrib>Vague, P</creatorcontrib><creatorcontrib>Tsimaratos, M</creatorcontrib><title>C-peptide replacement improves weight gain and renal function in diabetic rats</title><title>Diabetes & metabolism</title><addtitle>Diabetes Metab</addtitle><description><![CDATA[Recent experimental and clinical data suggest that C-peptide replacement during type 1 diabetes exerts beneficial effects on diabetic nephropathy. The aim of this study was to determine if physiological C-peptide administration in replacement dose during 28 days had beneficial effects on metabolic status and renal functions in type-1 diabetic rats.
Four groups of rats were investigated: a non diabetic group treated with buffer (C group, n=6), three streptozotocin diabetic-induced groups treated with either buffer (D group, n=6), insulin (D-I group, n=6) or rat homologous C-peptide (D-C group, n=6). Weight gain was measured every week. All animals were housed in metabolic cages on day 28 for assessment of metabolic data. Blood and urine samples were collected to allow measurement of plasmatic osmolality, C-peptide concentration, sodium, and glucose losses and proteinuria. Glomerular filtration rate (GFR) was determined by crea-tinine clearance.
All streptozotocin-treated animals were diabetic. Glycaemic control (mg/dl), was markedly improved in D-I (133±65) when compared with either D (547±49, P<0.05) or D-C (520±48, P<0.05) groups. Conversely, weight gain during the study, was improved in D-I and D-C as compared with D animals (135±13 and 41±18 vs 18±21 respectively), despite different glycaemic control. Diabetes-induced glomerular hyperfiltration (ml/min/kg), urinary protein leakage (g/kg/day), and Na urinary losses (mmol/100 g/day) respectively, were significantly (P<0.05) reduced in D-C (3.95±0.6; 0.08±0.06; 1.5±0.9) in comparison with D (4.95±0.8; 0.18±0.16; 3.7±2.1) and D-I (5±0.9; 0.19±0.11; 2.7±0.8) animals. Plasmatic osmolality was significantly increased in D group whereas there were no differences between C group and D-C group. Food and water intakes, urinary volume as well as urinary glucose losses were not significantly different between D-C and D groups.
C-peptide administration in replacement dose to strep-tozotocin diabetic rats induces weight gain regardless hyperglycaemia or glycosuria. Diabetic animals supplemented with C-peptide exhibit better renal function resulting in reduced urinary sodium waste and protein excretion together with reduction of the diabetes-induced glomerular hyperfiltration.
La supplémentation en peptide-C améliore la prise de poids et les fonctions rénales du rat diabétique
Des données expérimentales et cliniques récentes ont montré que la supplémentation en peptide-C avait des effets bénéfiques sur l'atteinte rénale du diabète de type 1. L'objectif de ce travail était de déterminer les effets d'une supplémentation en peptide-C à des doses physiologiques, pendant 28 jours, sur le statut métabolique et les fonctions rénales du rat diabétique.
Quatre groupes de rats ont été étudiés : un groupe de rats non diabétiques supplémentés avec une solution saline (groupe C, n = 6) et trois groupes de rats diabétiques (streptozotocine, IV), sup-plémentés respectivement avec une solution saline (groupe D, n = 6), de l'insuline (groupe D-I, n = 6) et du peptide-C (groupe D-C, n = 6). Les rats ont été pesés chaque semaine. À la fin de la période d'étude, les animaux ont été placés dans des cages métaboliques. Différents paramètres biologiques ont été mesurés : l'osmolalité plasmatique, les concentrations plasmatiques en peptide-C, sodium et glucose, la glycosurie, la natriurèse et la protéinurie. Le débit de filtration glomérulaire (GFR) a été déterminé par la clairance de la créatinine.
Tous les rats traités avec la streptozotocine étaient diabétiques. La glycémie (mg/ml) a été rétablie dans le groupe D-I (133 ± 65) comparé au groupe D (547 ± 49, P < 0,05) ou D-C (520 ± 48, P < 0,05). La prise de poids a été améliorée dans les groupes D-I et D-C comparés au groupe D (135 ± 13 et 41 ± 18 vs 18 ± 21 respectivement), indifféremment de la glycémie. L'hyperfiltration glomérulaire (ml/min/kg) induite par le diabète ainsi que la protéinurie (g/kg/jour) et la perte de sodium (mmol/100 g/day) ont été significativement réduites (P < 0,05) dans le groupe D-C (3,95 ± 0,6; 0,08 ± 0,06; 1,5 ± 0,9) comparé aux groupes D (4,95 ± 0,8; 0,18 ± 0,16; 3,7 ± 2,1) et D-I (5 ± 0,9; 0,19 ± 0,11; 2,7 ± 0,8). Les quantités de nourriture et d'eau, le volume urinaire, ainsi que la glycosurie n'étaient pas significative-ment différents entre les groupes D-C et D.
La supplémentation en peptide-C pendant un mois de rats diabétiques améliore la prise de poids indépendamment de l'hyperglycémie ou de la glycosurie. Elle entraîne également une amélioration de la fonction rénale, par comparaison aux rats diabétiques non supplémentés, en réduisant la perte de sodium urinaire, la protéinurie et l'hyperfiltration glomérulaire.]]></description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>C-peptide</subject><subject>C-Peptide - blood</subject><subject>C-Peptide - therapeutic use</subject><subject>Diabetes Mellitus, Experimental - blood</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - physiopathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - prevention & control</subject><subject>Diabetic nephropathy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Glomerular hyperfiltration</subject><subject>Hyperfiltration glomérulaire</subject><subject>Insulin - blood</subject><subject>Kidney - drug effects</subject><subject>Kidney - physiopathology</subject><subject>Kidneys</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Néphropathie diabétique</subject><subject>Peptide-C</subject><subject>Perte de sodium</subject><subject>Prise de poids</subject><subject>Proteinuria</subject><subject>Protéinurie</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Sodium - urine</subject><subject>Sodium losses</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><subject>Weight gain</subject><subject>Weight Gain - drug effects</subject><issn>1262-3636</issn><issn>1878-1780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1PwzAMhiMEYjD4CaBeQHAoJM2apCeEJr4kBAfgHHmpC0FtWpJsiH9PYEM7cooVP7ZfPYQcMHrGKBPnT6wQRc4FFydUnkpayCKnG2SHKalyJhXdTPUfMiK7IbxTyoqKq20yYkJWFa_UDnmY5gMO0daYeRxaMNihi5ntBt8vMGSfaF_fYvYK1mXg6gQ5aLNm7ky0vcvSb21hhtGazEMMe2SrgTbg_uodk5frq-fpbX7_eHM3vbzPDa94zJXEQoqyYU1lGPAUpqaqFHxCayOBi9QTnJVQcZjNGDCsGmpEo8qyFIwKzsfkeLk3xfyYY4i6s8Fg24LDfh60UKUUyUQCyyVofB-Cx0YP3nbgvzSj-kek_hWpfyxpKvWvSE3T3OHqwHzWYb2eWplLwNEKgGCgbTw4Y8OaS7fVZCITd7HkMOlYWPQ6GIvOYG09mqjr3v4T5RsOmI6G</recordid><startdate>20060601</startdate><enddate>20060601</enddate><creator>Rebsomen, L</creator><creator>Pitel, S</creator><creator>Boubred, F</creator><creator>Buffat, C</creator><creator>Feuerstein, JM</creator><creator>Raccah, D</creator><creator>Vague, P</creator><creator>Tsimaratos, M</creator><general>Elsevier Masson SAS</general><general>Masson</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060601</creationdate><title>C-peptide replacement improves weight gain and renal function in diabetic rats</title><author>Rebsomen, L ; Pitel, S ; Boubred, F ; Buffat, C ; Feuerstein, JM ; Raccah, D ; Vague, P ; Tsimaratos, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-87e2765f1f9c1a3799d0856340dc7a367656315a93abb1a1e9f0c6f8555610633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>C-peptide</topic><topic>C-Peptide - blood</topic><topic>C-Peptide - therapeutic use</topic><topic>Diabetes Mellitus, Experimental - blood</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - physiopathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - prevention & control</topic><topic>Diabetic nephropathy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Glomerular hyperfiltration</topic><topic>Hyperfiltration glomérulaire</topic><topic>Insulin - blood</topic><topic>Kidney - drug effects</topic><topic>Kidney - physiopathology</topic><topic>Kidneys</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Néphropathie diabétique</topic><topic>Peptide-C</topic><topic>Perte de sodium</topic><topic>Prise de poids</topic><topic>Proteinuria</topic><topic>Protéinurie</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Sodium - urine</topic><topic>Sodium losses</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><topic>Weight gain</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rebsomen, L</creatorcontrib><creatorcontrib>Pitel, S</creatorcontrib><creatorcontrib>Boubred, F</creatorcontrib><creatorcontrib>Buffat, C</creatorcontrib><creatorcontrib>Feuerstein, JM</creatorcontrib><creatorcontrib>Raccah, D</creatorcontrib><creatorcontrib>Vague, P</creatorcontrib><creatorcontrib>Tsimaratos, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rebsomen, L</au><au>Pitel, S</au><au>Boubred, F</au><au>Buffat, C</au><au>Feuerstein, JM</au><au>Raccah, D</au><au>Vague, P</au><au>Tsimaratos, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C-peptide replacement improves weight gain and renal function in diabetic rats</atitle><jtitle>Diabetes & metabolism</jtitle><addtitle>Diabetes Metab</addtitle><date>2006-06-01</date><risdate>2006</risdate><volume>32</volume><issue>3</issue><spage>223</spage><epage>228</epage><pages>223-228</pages><issn>1262-3636</issn><eissn>1878-1780</eissn><abstract><![CDATA[Recent experimental and clinical data suggest that C-peptide replacement during type 1 diabetes exerts beneficial effects on diabetic nephropathy. The aim of this study was to determine if physiological C-peptide administration in replacement dose during 28 days had beneficial effects on metabolic status and renal functions in type-1 diabetic rats.
Four groups of rats were investigated: a non diabetic group treated with buffer (C group, n=6), three streptozotocin diabetic-induced groups treated with either buffer (D group, n=6), insulin (D-I group, n=6) or rat homologous C-peptide (D-C group, n=6). Weight gain was measured every week. All animals were housed in metabolic cages on day 28 for assessment of metabolic data. Blood and urine samples were collected to allow measurement of plasmatic osmolality, C-peptide concentration, sodium, and glucose losses and proteinuria. Glomerular filtration rate (GFR) was determined by crea-tinine clearance.
All streptozotocin-treated animals were diabetic. Glycaemic control (mg/dl), was markedly improved in D-I (133±65) when compared with either D (547±49, P<0.05) or D-C (520±48, P<0.05) groups. Conversely, weight gain during the study, was improved in D-I and D-C as compared with D animals (135±13 and 41±18 vs 18±21 respectively), despite different glycaemic control. Diabetes-induced glomerular hyperfiltration (ml/min/kg), urinary protein leakage (g/kg/day), and Na urinary losses (mmol/100 g/day) respectively, were significantly (P<0.05) reduced in D-C (3.95±0.6; 0.08±0.06; 1.5±0.9) in comparison with D (4.95±0.8; 0.18±0.16; 3.7±2.1) and D-I (5±0.9; 0.19±0.11; 2.7±0.8) animals. Plasmatic osmolality was significantly increased in D group whereas there were no differences between C group and D-C group. Food and water intakes, urinary volume as well as urinary glucose losses were not significantly different between D-C and D groups.
C-peptide administration in replacement dose to strep-tozotocin diabetic rats induces weight gain regardless hyperglycaemia or glycosuria. Diabetic animals supplemented with C-peptide exhibit better renal function resulting in reduced urinary sodium waste and protein excretion together with reduction of the diabetes-induced glomerular hyperfiltration.
La supplémentation en peptide-C améliore la prise de poids et les fonctions rénales du rat diabétique
Des données expérimentales et cliniques récentes ont montré que la supplémentation en peptide-C avait des effets bénéfiques sur l'atteinte rénale du diabète de type 1. L'objectif de ce travail était de déterminer les effets d'une supplémentation en peptide-C à des doses physiologiques, pendant 28 jours, sur le statut métabolique et les fonctions rénales du rat diabétique.
Quatre groupes de rats ont été étudiés : un groupe de rats non diabétiques supplémentés avec une solution saline (groupe C, n = 6) et trois groupes de rats diabétiques (streptozotocine, IV), sup-plémentés respectivement avec une solution saline (groupe D, n = 6), de l'insuline (groupe D-I, n = 6) et du peptide-C (groupe D-C, n = 6). Les rats ont été pesés chaque semaine. À la fin de la période d'étude, les animaux ont été placés dans des cages métaboliques. Différents paramètres biologiques ont été mesurés : l'osmolalité plasmatique, les concentrations plasmatiques en peptide-C, sodium et glucose, la glycosurie, la natriurèse et la protéinurie. Le débit de filtration glomérulaire (GFR) a été déterminé par la clairance de la créatinine.
Tous les rats traités avec la streptozotocine étaient diabétiques. La glycémie (mg/ml) a été rétablie dans le groupe D-I (133 ± 65) comparé au groupe D (547 ± 49, P < 0,05) ou D-C (520 ± 48, P < 0,05). La prise de poids a été améliorée dans les groupes D-I et D-C comparés au groupe D (135 ± 13 et 41 ± 18 vs 18 ± 21 respectivement), indifféremment de la glycémie. L'hyperfiltration glomérulaire (ml/min/kg) induite par le diabète ainsi que la protéinurie (g/kg/jour) et la perte de sodium (mmol/100 g/day) ont été significativement réduites (P < 0,05) dans le groupe D-C (3,95 ± 0,6; 0,08 ± 0,06; 1,5 ± 0,9) comparé aux groupes D (4,95 ± 0,8; 0,18 ± 0,16; 3,7 ± 2,1) et D-I (5 ± 0,9; 0,19 ± 0,11; 2,7 ± 0,8). Les quantités de nourriture et d'eau, le volume urinaire, ainsi que la glycosurie n'étaient pas significative-ment différents entre les groupes D-C et D.
La supplémentation en peptide-C pendant un mois de rats diabétiques améliore la prise de poids indépendamment de l'hyperglycémie ou de la glycosurie. Elle entraîne également une amélioration de la fonction rénale, par comparaison aux rats diabétiques non supplémentés, en réduisant la perte de sodium urinaire, la protéinurie et l'hyperfiltration glomérulaire.]]></abstract><cop>Paris</cop><pub>Elsevier Masson SAS</pub><pmid>16799398</pmid><doi>10.1016/S1262-3636(07)70272-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1262-3636 |
| ispartof | Diabetes & metabolism, 2006-06, Vol.32 (3), p.223-228 |
| issn | 1262-3636 1878-1780 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68576878 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Biological and medical sciences Blood Glucose - drug effects Blood Glucose - metabolism C-peptide C-Peptide - blood C-Peptide - therapeutic use Diabetes Mellitus, Experimental - blood Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - physiopathology Diabetes. Impaired glucose tolerance Diabetic Angiopathies - prevention & control Diabetic nephropathy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Glomerular hyperfiltration Hyperfiltration glomérulaire Insulin - blood Kidney - drug effects Kidney - physiopathology Kidneys Male Medical sciences Nephrology. Urinary tract diseases Néphropathie diabétique Peptide-C Perte de sodium Prise de poids Proteinuria Protéinurie Rats Rats, Sprague-Dawley Sodium - urine Sodium losses Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Weight gain Weight Gain - drug effects |
| title | C-peptide replacement improves weight gain and renal function in diabetic rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C-peptide%20replacement%20improves%20weight%20gain%20and%20renal%20function%20in%20diabetic%20rats&rft.jtitle=Diabetes%20&%20metabolism&rft.au=Rebsomen,%20L&rft.date=2006-06-01&rft.volume=32&rft.issue=3&rft.spage=223&rft.epage=228&rft.pages=223-228&rft.issn=1262-3636&rft.eissn=1878-1780&rft_id=info:doi/10.1016/S1262-3636(07)70272-0&rft_dat=%3Cproquest_cross%3E68576878%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68576878&rft_id=info:pmid/16799398&rft_els_id=S1262363607702720&rfr_iscdi=true |